Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
AlphaBet trial: what clinicians have said so far
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer
- NCT05383079 ↗
- Active, not recruiting
- Peter MacCallum Cancer Centre, Australia
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on AlphaBet (lutetium-177 PSMA-I&T plus radium-223 in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AlphaBet so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 7 posts on X, typically up to 31 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer; MCRPC; Prostate Cancer
- Interventions
- Lutetium-177 PSMA-I&T; Radium-223
- Arms
- Radium-223 and Lutetium-177 PSMA-I&T · Experimental
- Enrollment
- 36 (estimated)
- Primary outcomes
- Dose Limiting toxicities (DLTs)
- Maximum Tolerated dose (MTD)
- Recommended Phase 2 Dose (RP2D)
- 50% Prostate-Specific Antigen Response Rate (PSA-RR)
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Start
- Sep 13, 2022
- Primary completion
- Aug 1, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05383079 · updated Feb 7, 2025
Publications
linked from the registry- Kostos L, Buteau JP, Xie J, Cardin A, Akhurst T, Alipour R, Au L, Chan J, Chin KY, Emmerson B, Furic L, Garcia Q, Hamilton AJ, Haskali MB, Jackson PA, Kashyap RK, Kong G, MacFarlane L, Murphy DG, Parker BS, Ravi Kumar AS, Saghebi J, Wang Y, Tran B, Azad AA, Hofman MS. Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial. Lancet Oncol. 2025 Nov;26(11):1479-1488. doi: 10.1016/S1470-2045(25)00559-5. Epub 2025 Oct 18. PubMed 41119954
- Kostos L, Buteau JP, Yeung T, Iulio JD, Xie J, Cardin A, Chin KY, Emmerson B, Owen KL, Parker BS, Fettke H, Furic L, Azad AA, Hofman MS. AlphaBet: Combination of Radium-223 and [17 7Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med (Lausanne). 2022 Nov 18;9:1059122. doi: 10.3389/fmed.2022.1059122. eCollection 2022. PubMed 36465905